Drug intelligence / Profile preview

lutetium Lu 177 PSMA I&T

Development stage: Discontinued
Lead developer: Curium
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Lutetium Lu-177 PSMA I&T is a targeted radiopharmaceutical therapy designed for the treatment of prostate cancer. It consists of the beta-emitting radioisotope lutetium-177 (177Lu) conjugated to the PSMA I&T (Imaging & Therapy) ligand, a small molecule that specifically binds to prostate-specific membrane antigen (PSMA). PSMA is a transmembrane protein that is significantly overexpressed in prostate cancer cells, particularly in metastatic and castration-resistant stages. Upon intravenous administration, the drug binds to PSMA-positive tumor cells and is internalized, allowing the lutetium-177 to deliver localized, high-energy beta radiation that induces DNA damage and subsequent cell death. Originally developed at the Technical University of Munich and licensed to Scintomics and Curium, it is currently being evaluated in major clinical trials, including the Phase 3 ECLIPSE trial for metastatic castration-resistant prostate cancer (mCRPC) and the BULLSEYE trial for hormone-sensitive prostate cancer.

Brand names: Lutetium-177 PSMA I&T
Other names: Lutetium Lu-177 PSMA I&T[177Lu]Lu-PSMA-I&TLutetium-177 PSMA I&T

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on lutetium Lu 177 PSMA I&T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lutetium Lu 177 PSMA I&T.

Explore the full profile